Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olof Bengtsson

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Acta Oncologica (Stockholm, Sweden)|February 9, 2011
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Johan Ahlgren, Karsten Bjerre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancerJohanna Sjöström, Carl Blomqvist, Kristina von Boguslawski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancerBent Ejlertsen, Henning T Mouridsen, Maj-Britt Jensen, et al.
Cancers|November 11, 2022
Radiofrequency Electromagnetic Fields Cause Non-Temperature-Induced Physical and Biological Effects in Cancer CellsPeter Wust, Paraskevi D Veltsista, Eva Oberacker, et al.
Acta Oncologica (Stockholm, Sweden)|December 23, 2010
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils-Olof Bengtsson, Lena Carlsson, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2011
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and SwedenPaul McGale, Sarah C Darby, Per Hall, et al.
European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Acta Oncologica (Stockholm, Sweden)|May 7, 2002
Physical performance, toxicity, and quality of life as assessed by the physician and the patientMinna-Liisa Luoma, Liisa Hakamies-Blomqvist, Johanna Sjöström, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Acta Oncologica (Stockholm, Sweden)|February 9, 2011
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Johan Ahlgren, Karsten Bjerre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancerJohanna Sjöström, Carl Blomqvist, Kristina von Boguslawski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancerBent Ejlertsen, Henning T Mouridsen, Maj-Britt Jensen, et al.
Cancers|November 11, 2022
Radiofrequency Electromagnetic Fields Cause Non-Temperature-Induced Physical and Biological Effects in Cancer CellsPeter Wust, Paraskevi D Veltsista, Eva Oberacker, et al.
Acta Oncologica (Stockholm, Sweden)|December 23, 2010
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils-Olof Bengtsson, Lena Carlsson, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2011
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and SwedenPaul McGale, Sarah C Darby, Per Hall, et al.
European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Acta Oncologica (Stockholm, Sweden)|May 7, 2002
Physical performance, toxicity, and quality of life as assessed by the physician and the patientMinna-Liisa Luoma, Liisa Hakamies-Blomqvist, Johanna Sjöström, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Pageof 8